Brainstorm announces presentations at june 2022 scientific conferences

Analyses accounting for alsfrs-r floor effect in als yields new results to be presented at the encals meeting in edinburgh, scotland clinical, biomarker and preclinical data from nurown® phase 2 clinical trial in ms to be presented at cmsc meeting in national harbor, md, usa new york , may 31, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at forthcoming als and ms scientific conferences in june 2022.  insights into the als phase 3 primary endpoint leveraging encals model patient prognosis trajectories will be presented as a scientific poster at the european network to cure als (encals) meeting in edinburgh, scotland june 1-3, 2022.
BCLI Ratings Summary
BCLI Quant Ranking